Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094). (Q40417855)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094).	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094). (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

0 references

0 references

Dominique Costagliola

12

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Christine Katlama

15

object named as

Christine Katlama

0 references

9

object named as

Anne Simon

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

author name string

Roland Tubiana

1

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Guislaine Carcelain

2

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Muriel Vray

3

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Karine Gourlain

4

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Cécile Dalban

5

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Aziza Chermak

6

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Claire Rabian

7

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Daniel Vittecoq

8

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Elisabeth Bouvet

10

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Raphaelle El Habib

11

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Vincent Calvez

13

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Brigitte Autran

14

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Vacciter Study group

16

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

language of work or name

0 references

publication date

1 July 2005

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

23

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

34

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

4292-4301

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.013

7 January 2021

Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.013

7 January 2021

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.013

7 January 2021

Combination antiretroviral therapy and the risk of myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.013

7 January 2021

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.013

7 January 2021

Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.013

7 January 2021

Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.013

7 January 2021

Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.013

7 January 2021

Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.013

7 January 2021

Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.013

7 January 2021

HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.013

7 January 2021

Dynamics of HIV-specific CD8+ T lymphocytes with changes in viral load.The RESTIM and COMET Study Groups

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.013

7 January 2021

An antigenic threshold for maintaining human immunodeficiency virus type 1-specific cytotoxic T lymphocytes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.013

7 January 2021

HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.013

7 January 2021

HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.013

7 January 2021

Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.013

7 January 2021

HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.013

7 January 2021

Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.013

7 January 2021

HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.013

7 January 2021

The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.013

7 January 2021

HIV preferentially infects HIV-specific CD4+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.013

7 January 2021

Evaluating therapeutic vaccines in patients infected with HIV.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.013

7 January 2021

Viremia control following antiretroviral treatment and therapeutic immunizationduring primary SIV251 infection of macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.013

7 January 2021

Vaccination of macaques with long-standing SIVmac251 infection lowers the viral set point after cessation of antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.013

7 January 2021

Enhancement of human immunodeficiency virus (HIV)-specific CD4+ and CD8+ cytotoxic T-lymphocyte activities in HIV-infected asymptomatic patients given recombinant gp160 vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.013

7 January 2021

Therapeutic immunisation with recombinant gp160 in HIV-1 infection: a randomised double-blind placebo-controlled trial. Nordic VAC-04 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.013

7 January 2021

DNA immunization with HIV early genes in HIV type 1-infected patients on highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.013

7 January 2021

Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.013

7 January 2021

A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.013

7 January 2021

Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-1)-negative volunteers immunized with a recombinant canarypox expressing gp 160 of HIV-1 and boosted with a recombinant gp160.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.013

7 January 2021

Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.013

7 January 2021

Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.013

7 January 2021

One-sample multiple testing procedure for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.013

7 January 2021

Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.013

7 January 2021

HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.013

7 January 2021

Immunological and virological factors at baseline may predict response to structured therapy interruption in early stage chronic HIV-1 infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.013

7 January 2021

Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.013

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2005.04.013

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40417855&oldid=1507629632"